Related Experiment Videos
Delayed reactions to contrast media after interleukin-2 immunotherapy
P L Choyke1, D L Miller, M T Lotze
1Diagnostic Radiology Department, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Radiology
|April 1, 1992
Summary
Patients receiving interleukin-2 (IL-2) experienced more frequent delayed reactions to contrast media. These reactions, including rash and flu-like symptoms, were generally mild but more severe in IL-2 patients.
Area of Science:
- Radiology
- Immunology
- Pharmacology
Background:
- Interleukin-2 (IL-2) therapy is associated with various side effects.
- Contrast media are commonly used in diagnostic imaging.
- The potential for delayed reactions to contrast media in IL-2 patients is not well-established.
Purpose of the Study:
- To determine the prevalence of delayed adverse reactions to intravenous (iopamidol) and oral (diatrizoate sodium) contrast media in patients who received IL-2.
- To compare the incidence and severity of these reactions between IL-2 recipients and non-recipients.
Main Methods:
- A prospective study utilizing questionnaires.
- 170 patients who received IL-2 and 631 patients who did not were assessed for delayed reactions.
- A control group of 100 non-IL-2 patients received only oral contrast medium.
Main Results:
- Delayed reactions occurred in 11.8% of IL-2 patients versus 3.9% of non-IL-2 patients.
- Reactions were more severe in IL-2 patients, with two requiring hospitalization.
- Rash, flulike symptoms, and pruritus were statistically more common in IL-2 patients.
Conclusions:
- The prevalence of delayed reactions to nonionic contrast media is higher in patients who have received IL-2.
- Most delayed reactions are mild and do not require specific therapy.
- Healthcare providers should be aware of increased reaction risk in IL-2 patients.